Pharmacokinetics and pharmacodynamics of intravenous and inhaled fluticasone furoate in healthy Caucasian and East Asian subjects

British Journal of Clinical Pharmacology

Volumn 77, Issue 5, 2014, Pages 808-820

  Allen, Ann ^a   Bal, Joanne ^a   Cheesbrough, Anne ^a   Hamilton, Melanie ^a   Kempsford, Rodger ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Caucasian; East Asian; fluticasone furoate; healthy subjects; pharmacodynamics; pharmacokinetics

Indexed keywords

CYTOCHROME P450 3A4; ELLIPTA; FLUTICASONE FUROATE; HYDROCORTISONE; UNCLASSIFIED DRUG; ANDROSTANE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASIAN; CAUCASIAN; CHINESE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRY POWDER INHALER; ENZYME ACTIVITY; ETHNIC DIFFERENCE; EXPOSURE; FEMALE; HEADACHE; HUMAN; HYDROCORTISONE BLOOD LEVEL; IN VITRO STUDY; JAPANESE (PEOPLE); KOREAN; LUNG; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PARTICLE SIZE; PATIENT COMPLIANCE; PLASMA CLEARANCE; PLASMA CONCENTRATION-TIME CURVE; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIMULATION; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; ASIAN CONTINENTAL ANCESTRY GROUP; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION;

ADMINISTRATION, INHALATION; ANDROSTADIENES; ASIAN CONTINENTAL ANCESTRY GROUP; CROSS-OVER STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE;

EID: 84899472216     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12263     Document Type: Article

References (20)

1. Lötvall J, Bakke PS, Bjermer L, Steinshamn S, Scott-Wilson C, Crim C, Sanford L, Haumann B,. Efficacy and safety of 4 weeks' treatment with combined fluticasone furoate/vilanterol in a single inhaler given once daily in COPD: a placebo-controlled randomised trial. BMJ Open 2012; 2: e000370.
2. Kempsford RD, Allen A, Bareille P, Bishop H, Hamilton M, Cheesbrough A,. The safety, tolerability, pharmacodynamics and pharmacokinetics of inhaled fluticasone furoate (FF) and vilanterol (VI) are unaffected by administration in combination. ERJ 2011; 38: (Suppl. 55): 138s.
3. Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren J-E,. Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects. Br J Clin Pharmacol 1997; 43: 155-161.
4. Bernstein DI, Allen DB,. Evaluation of tests of hypothalamic-pituitary- adrenal axis function used to measure effects of inhaled corticosteroids. Ann Allergy Asthma Immunol 2007; 98: 118-127.
5. Salpeter SR, Ormiston TM, Salpeter EE,. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest 2004; 125: 2309-2321.
6. Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE,. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 2006; 144: 904-912.
7. Boscia JA, Pudi KK, Zvarich MT, Sanford L, Siederer SK, Crim C,. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with COPD: a randomized, three-way, incomplete block, crossover study. Clin Ther 2012; 34: 1655-1666.e5.
8. Agusti A, De Backer W, de Teresa L, Zvarich M, Locantore N, Barnes N, Bourbeau J, Crim C,. Efficacy of combination fluticasone furoate/vilanterol (FF/VI) and salmeterol/fluticasone propionate (SFC) over 12 weeks in patients with COPD. Eur Respir J 2012; 40: (Suppl. 56): 527-528s.
9. Bleecker ER, Lötvall J, O'Bryne PM, Woodcock A, Busse WW, Forth R, Medley H, Nunn C, Jacques L, Bateman ED,. Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12 weeks in patients with persistent asthma. Eur Respir J 2012; 40: (Suppl. 56): 370s.
10. O'Byrne PM, Bleecker ER, Bateman ED, Busse WW, Woodcock A, Forth R, Toler T, Jacques L, Lötvall J,. Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) once daily (OD) for 24 weeks in persistent asthma. Eur Respir J 2012; 40: (Suppl. 56): 313s.
11. Woodcock A, Bleecker ER, Lötvall J, O'Byrne PM, Bateman ED, Medley H, Ellsworth A, Jacques L, Busse WW,. Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) compared with fluticasone propionate/salmeterol combination (FP/SAL) in adults and adolescents with persistent asthma. Eur Respir J 2012; 40: (Suppl. 56): 313s.
12. Hughes SC, Shardlow PG, Hollis FJ, Scott RJ, Motivaras DS, Allen A, Rousell VM,. Metabolism and disposition of fluticasone furoate, an enhanced affinity glucocorticoid, in humans. Drug Metab Dispos 2008; 36: 2337-2344.
13. Myrand SP, Sekiguchi K, Man MZ, Lin X, Tzeng RY, Teng CH, Hee B, Garrett M, Kikkawa H, Lin CY, Eddy SM, Dostalik J, Mount J, Azuma J, Fujio Y, Jang IJ, Shin SG, Bleavins MR, Williams JA, Paulauskis JD, Pharmacokinetics/genotype WKD,. associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations. Clin Pharmacol Ther 2008; 84: 347-361.
14. Burnell PKP, Malton A, Reavill K, Ball MHE,. Design, validation and initial testing of the electronic lung™ device. J Aerosol Sci 1998; 29: 1011-1025.
15. Loo JCK, Riegelman S,. New method for calculating the intrinsic absorption rate of drugs. J Pharm Sci 1968; 57: 918-928.
16. Allen A, Apoux L, Bal J, Bianco J, Moore A, Ravindranath R, Tombs L, Kempsford R,. The pharmacokinetics of fluticasone furoate and vilanterol following single inhaled administration in combination and intravenous administration of individual components in healthy subjects. J Bioequiv Availab 2013; 5: 165-173.
17. Allen A, Bareille PJ, Rousell VM,. Fluticasone furoate, a novel inhaled corticosteroid, demonstrates prolonged lung absorption kinetics in man compared with inhaled fluticasone propionate. Clin Pharmacokinet 2013; 52: 37-42.
18. Allen A,. The relationship between fluticasone furoate systemic exposure and cortisol suppression. Clin Pharmacokinet 2013; 52: 885-896.
19. Busse WW, Bleecker ER, Bateman ED, Lötvall J, Forth R, Davis AM, Jacques L, Haumann B, Woodcock A,. Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial. Thorax 2012; 67: 35-41.
20. Bateman ED, Bleecker ER, Lötvall J, Woodcock A, Forth R, Medley H, Davis AM, Jacques L, Haumann B, Busse WW,. Dose effect of once-daily fluticasone furoate in persistent asthma: a randomized trial. Respir Med 2012; 106: 642-650.